Comments*

 
  • Academy Events

  • Progressive Multifocal Leukoencephalopathy

    June 19 - 20, 2013
    The New York Academy of Sciences

    Presented by the Progressive Multifocal Leukoencephalopathy Consortium and The New York Academy of Sciences

    Progressive Multifocal Leukoencephalopathy (PML) is, in the general population, a rare but serious demyelinating disease of the brain, often resulting in severe disability or death and is caused by infection of oligodendrocytes by the JC polyomavirus (JCV). It is believed that fifty to sixty percent of the population is sero-positive for JCV, indicating exposure to the virus. Despite the high prevalence of JCV infection in the human population, which typically leads to a chronic, asymptomatic infection, incidence of PML in the general population is very low. The pathogenesis of PML is not well understood. It is believed that the development of PML, while dependent on the presence of JCV, is the result of a confluence of viral and host risk factors, which may include an altered or compromised immune system such as in individuals with HIV-1 infection/acquired immune deficiency syndrome (AIDS), or patients undergoing chronic immunosuppressive therapies after organ transplantation, for treatment of lymphomas, or for autoimmune conditions, such as MS.

    This 2-day conference will bring together basic science researchers, clinicians, physicians, epidemiologists, and regulatory experts from academia, industry, and government to address novel issues, current challenges, and future directions of basic and clinical research relevant to the mitigation, potential future cure, and risk stratification of PML. Topics of discussion will include JCV virology, PML pathogenesis, risk stratification and disease diagnosis and management. The meeting will feature a series of plenary lectures, short talk presentations selected from submitted abstracts, a poster session, and a closing panel discussion.

    Conference Planning Committee

    Claudio Carini, MD

    Pfizer Inc.

    Teresa Compton, PhD

    Biogen Idec (Conference Chair)

    Marion Kasaian, PhD

    Pfizer Inc.

    Theodora Salcedo, PhD

    Bristol-Myers Squibb Company

    Anne Vogt, PhD

    F. Hoffmann-La Roche Ltd

    Scientific Advisory Board

    Leonard H. Calabrese, DO

    Cleveland Clinic

    Paola Cinque, MD, PhD

    San Raffaele Scientific Institute

    David B. Clifford, MD

    Washington University School of Medicine

    Robert L. Garcea, MD

    University of Colorado at Boulder

    Eugene O. Major, PhD

    National Institute of Neurological Disorders and Stroke

    Kenneth Tyler, MD

    University of Colorado School of Medicine

    Thomas Weber, MD

    University of Hamburg

    Registration Pricing

      By 5/13/2013 After 5/13/2013 Onsite
    Member $125 $150 $175
    Student/Postdoc Member $75 $100 $125
    Nonmember (Academia) $150 $185 $225
    Nonmember (Corporate) $185 $225 $265
    Nonmember (Non-profit) $150 $185 $225
    Nonmember (Student / Postdoc / Fellow) $75 $100 $125

     

    Registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.

    Presented by

    • NYAS
    • Progressive Multifocal Leukoencephalopathy Consortium
    EmailPrint